Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Serum amyloid A3 is a high density lipoprotein-associated acute-phase protein

  • Lisa R. Tannock
  • , Maria C. De Beer
  • , Ailing Ji
  • , Preetha Shridas
  • , Victoria P. Noffsinger
  • , Laura Den Hartigh
  • , Alan Chait
  • , Frederick C. De Beer
  • , Nancy R. Webb

Producción científica: Articlerevisión exhaustiva

51 Citas (Scopus)

Resumen

Serum amyloid A (SAA) is a family of acute-phase reactants. Plasma levels of human SAA1/SAA2 (mouse SAA1.1/2.1) can increase ≥1,000-fold during an acute-phase response. Mice, but not humans, express a third relatively understudied SAA isoform, SAA3. We investigated whether mouse SAA3 is an HDL-associated acute-phase SAA. Quantitative RT- PCR with isoform-specific primers indicated that SAA3 and SAA1.1/2.1 are induced similarly in livers (2,500-fold vs. 6,000-fold, respectively) and fat (400-fold vs. 100-fold, respectively) of lipopolysaccharide (LPS)-injected mice. In situ hybridization demonstrated that all three SAAs are produced by hepatocytes. All three SAA isoforms were detected in plasma of LPS-injected mice, although SAA3 levels were 20% of SAA1.1/2.1 levels. Fast protein LC analyses indicated that virtually all of SAA1.1/2.1 eluted with HDL, whereas 15% of SAA3 was lipid poor/free. After density gradient ultracentrifugation, isoelectric focusing demonstrated that 100% of plasma SAA1.1 was recovered in HDL compared with only 50% of SAA2.1 and 10% of SAA3. Thus, SAA3 appears to be more loosely associated with HDL, resulting in lipid-poor/free SAA3. We conclude that SAA3 is a major hepatic acute-phase SAA in mice that May produce systemic effects during inflammation.

Idioma originalEnglish
Páginas (desde-hasta)339-347
Número de páginas9
PublicaciónJournal of Lipid Research
Volumen59
N.º2
DOI
EstadoPublished - 2018

Nota bibliográfica

Funding Information:
This work was supported by the US Department of Veterans Affairs Awards CX000975 (L.R.T.) and CX000773 (N.R.W.) and National Institutes of Health Grants HL134731 (N.R.W., F.C.D.B.), HL092969 (A.C.), AT007177 (L.d.H.), and P20 GM103527 (support for used cores). Mass spectrometric analysis was performed at the University of Kentucky, Proteomics Core Facility. This core facility is supported in part by funds from the Office of the Vice President for Research. The content of this study is solely the responsibility of the authors and does not represent the official views of the US Department of Veterans Affairs, the National Institutes of Health, or the United States Government.

Funding Information:
This work was supported by the US Department of Veterans Affairs Awards CX000975 (L.R.T.) and CX000773 (N.R.W.) and National Institutes of Health Grants HL134731 (N.R.W., F.C.D.B.), HL092969 (A.C.), AT007177 (L.d.H.), and P20 GM103527 (support for used cores). Mass spectrometric analysis was performed at the University of Kentucky, Proteomics Core Facility. This core facility is supported in part by funds from the Office of the Vice President for Research. The content of this study is solely the responsibility of the authors and does not represent the official views of the US Department of Veterans Affairs, the National Institutes of Health, or the United States Government. Manuscript received 25 September 2017 and in revised form 22 November 2017. Published, JLR Papers in Press, December 15, 2017 DOI https://doi.org/10.1194/jlr.M080887

Financiación

This work was supported by the US Department of Veterans Affairs Awards CX000975 (L.R.T.) and CX000773 (N.R.W.) and National Institutes of Health Grants HL134731 (N.R.W., F.C.D.B.), HL092969 (A.C.), AT007177 (L.d.H.), and P20 GM103527 (support for used cores). Mass spectrometric analysis was performed at the University of Kentucky, Proteomics Core Facility. This core facility is supported in part by funds from the Office of the Vice President for Research. The content of this study is solely the responsibility of the authors and does not represent the official views of the US Department of Veterans Affairs, the National Institutes of Health, or the United States Government. This work was supported by the US Department of Veterans Affairs Awards CX000975 (L.R.T.) and CX000773 (N.R.W.) and National Institutes of Health Grants HL134731 (N.R.W., F.C.D.B.), HL092969 (A.C.), AT007177 (L.d.H.), and P20 GM103527 (support for used cores). Mass spectrometric analysis was performed at the University of Kentucky, Proteomics Core Facility. This core facility is supported in part by funds from the Office of the Vice President for Research. The content of this study is solely the responsibility of the authors and does not represent the official views of the US Department of Veterans Affairs, the National Institutes of Health, or the United States Government. Manuscript received 25 September 2017 and in revised form 22 November 2017. Published, JLR Papers in Press, December 15, 2017 DOI https://doi.org/10.1194/jlr.M080887

FinanciadoresNúmero del financiador
N.R.W.
US Department of Veterans Affairs Awards CX000975
Core Laboratories
Cores Science and Engineering Ltd.
National Institutes of Health (NIH)P20 GM103527, HL134731, HL092969
National Institutes of Health (NIH)
U.S. Department of Veterans AffairsCX000975, CX000773
U.S. Department of Veterans Affairs
National Center for Complementary and Integrative HealthK01AT007177
National Center for Complementary and Integrative Health
Office of the Vice President for Research, University of South Carolina

    ASJC Scopus subject areas

    • Biochemistry
    • Endocrinology
    • Cell Biology

    Huella

    Profundice en los temas de investigación de 'Serum amyloid A3 is a high density lipoprotein-associated acute-phase protein'. En conjunto forman una huella única.

    Citar esto